Literature DB >> 33078319

The Significance of Lateral Lymph Node Metastasis in Low Rectal Cancer: a Propensity Score Matching Study.

Liming Wang1, Yasumitsu Hirano2, Gregory Heng2, Toshimasa Ishii2, Hiroka Kondo2, Kiyoka Hara2, Nao Obara2, Masahiro Asari2, Shigeki Yamaguchi2.   

Abstract

BACKGROUND: The indications for lateral lymph node dissection (LLND) in rectal cancer have been controversial. The purpose of this study was to clarify the significance of lateral lymph node metastasis in low rectal cancer.
METHODS: This was a retrospective study at a high-volume cancer center in Japan. In this study, 40 patients with pathologically positive LLN (LLN+) were matched with 175 negative (LLN-) patients by propensity score matching (PSM). COX regression analysis was used to identify independent risk factors related to prognosis. The relapse-free survival rate (RFS) and overall survival rate (OS) of the 2 groups before and after matching were analyzed.
RESULTS: Of the 64 patients undergoing LLND, 40 (62.5%) patients had LLN+ disease. The LLN+ patients showed deeper infiltration of the primary tumor than the LLN- patients (T3-T4: 87.5% vs. 72.0%; p = 0.044), a greater number of metastatic lymph nodes (N2: 75.0% vs. 35.4%; p < 0.001), and a higher rate of local recurrence (30% vs. 9.1%; p < 0.001). Adjuvant chemotherapy was more common in the 40 LLN+ patients than in the 175 LLN- patients (70.0% vs. 46.8%; p = 0.008). After relapse, the rate of first-line chemotherapy administration for LLN+ patients was higher than that for the LLN- patients (62.5% vs. 29.5%; p = 0.005). The RFS of LLN+ patients was shorter than that of the LLN- patients (p = 0.005). After PSM, although more LLN+ patients received adjuvant chemotherapy than the LLN- patients (70.0% vs. 40.0%; p = 0.007), the local recurrence rate remained higher (30% vs. 10%; p = 0.025). The differences between RFS (p = 0.655) and OS rates (p = 0.164) of the 2 patient groups were not significant.
CONCLUSION: Even after LLND, patients with LLN+ low rectal cancer still showed an elevated local recurrence rate. Controlling local recurrence by adjuvant chemotherapy alone is difficult, and the additional strategic treatments are needed.
© 2020. The Society for Surgery of the Alimentary Tract.

Entities:  

Keywords:  Lateral lymph node dissection; Low rectal cancer; Propensity score matching

Mesh:

Year:  2020        PMID: 33078319     DOI: 10.1007/s11605-020-04825-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Impact of Lateral Pelvic Lymph Node Dissection on the Survival of Patients with T3 and T4 Low Rectal Cancer.

Authors:  Heita Ozawa; Kenjiro Kotake; Miki Hosaka; Akira Hirata; Kenichi Sugihara
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

2.  Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer.

Authors:  Y Moriya; K Sugihara; T Akasu; S Fujita
Journal:  World J Surg       Date:  1997-09       Impact factor: 3.352

3.  Indication and benefit of pelvic sidewall dissection for rectal cancer.

Authors:  Kenichi Sugihara; Hirotoshi Kobayashi; Tomoyuki Kato; Takeo Mori; Hidetaka Mochizuki; Shingo Kameoka; Kazuo Shirouzu; Tetsuichiro Muto
Journal:  Dis Colon Rectum       Date:  2006-11       Impact factor: 4.585

4.  Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection.

Authors:  Hideki Ueno; Hidetaka Mochizuki; Yojiro Hashiguchi; Megumi Ishiguro; Masayoshi Miyoshi; Yoshiki Kajiwara; Taichi Sato; Hideyuki Shimazaki; Kazuo Hase
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.

Authors:  Shin Fujita; Junki Mizusawa; Yukihide Kanemitsu; Masaaki Ito; Yusuke Kinugasa; Koji Komori; Masayuki Ohue; Mitsuyoshi Ota; Yoshihiro Akazai; Manabu Shiozawa; Takashi Yamaguchi; Hiroyuki Bandou; Kenji Katsumata; Kohei Murata; Yoshihito Akagi; Nobuhiro Takiguchi; Yoshihisa Saida; Kenichi Nakamura; Haruhiko Fukuda; Takayuki Akasu; Yoshihiro Moriya
Journal:  Ann Surg       Date:  2017-08       Impact factor: 12.969

6.  Total mesorectal excision, lateral lymphadenectomy and autonomic nerve preservation for lower rectal cancer: significance in the long-term follow-up study.

Authors:  K Shirouzu; Y Ogata; Y Araki; T Sasatomi; Y Nozoe; M Nakagawa; K Matono
Journal:  Kurume Med J       Date:  2001

7.  Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.

Authors:  Jin C Kim; Keiichi Takahashi; Chang S Yu; Hee C Kim; Tae W Kim; Min H Ryu; Jong H Kim; Takeo Mori
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

8.  Benefit of lateral lymph node dissection for rectal cancer: long-term analysis of 944 cases undergoing surgery at a single center (1975-2004).

Authors:  Tetsushi Kinugasa; Yoshito Akagi; Kazuo Shirouzu
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

9.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

Authors:  Yojiro Hashiguchi; Kei Muro; Yutaka Saito; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Kiyoshi Hasegawa; Kinichi Hotta; Hideyuki Ishida; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Yusuke Kinugasa; Keiko Murofushi; Takako Eguchi Nakajima; Shiro Oka; Toshiaki Tanaka; Hiroya Taniguchi; Akihito Tsuji; Keisuke Uehara; Hideki Ueno; Takeharu Yamanaka; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Michio Itabashi; Kentaro Sakamaki; Keiji Sano; Yasuhiro Shimada; Shinji Tanaka; Hiroyuki Uetake; Shigeki Yamaguchi; Naohiko Yamaguchi; Hirotoshi Kobayashi; Keiji Matsuda; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2019-06-15       Impact factor: 3.402

Review 10.  Controversies in the Management of Lateral Pelvic Lymph Nodes in Patients With Advanced Rectal Cancer: East or West?

Authors:  Jaime Otero de Pablos; Julio Mayol
Journal:  Front Surg       Date:  2020-01-17
View more
  3 in total

1.  Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis.

Authors:  Sicheng Zhou; Yujuan Jiang; Wei Pei; Jianwei Liang; Zhixiang Zhou
Journal:  BMC Surg       Date:  2021-12-28       Impact factor: 2.102

2.  Mesorectal excision with lateral lymph node dissection for mid-low rectal cancer with lateral lymph node metastasis: efficacy and prognostic analysis.

Authors:  Sicheng Zhou; Yujuan Jiang; Jianwei Liang; Qian Liu
Journal:  World J Surg Oncol       Date:  2022-03-29       Impact factor: 2.754

3.  Prognostic significance of lateral pelvic lymph node dissection for middle-low rectal cancer patients with lateral pelvic lymph node metastasis: a propensity score matching study.

Authors:  Sicheng Zhou; Yujuan Jiang; Wei Pei; Jianwei Liang; Zhixiang Zhou
Journal:  BMC Cancer       Date:  2022-02-03       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.